Articles

Kuraray deploys countermeasures in February

As a defense against possible unwanted takeover attempts, company moves to have more control over potential large-scale share purchases
| 8 min read

Continuation of Countermeasures (Takeover Defense) in Response to Large-scale Purchase of Kuraray Shares (Summary)

On Feb. 24, 2015, Kuraray Co. Ltd. announced that it had obtained the approval of shareholders concerning the introduction of the countermeasures (the "Current Plan") to large-scale purchases of the Company's shares at the Company's ordinary shareholders' meeting held on June 22, 2012, and introduced the Current Plan as of the same date. Thereafter, continuing to observe the progress of revision of the applicable laws, and based on recent development of understanding of takeover defense, the Company has reviewed the Current Plan.

As a result of its consideration, the Company has decided, at the meeting of its board of directors (the "Board of Directors") held today, to introduce the countermeasures (the "New Plan") described below in summary to large-scale purchases of the Company's shares, which will follow the Current Plan, on the condition that the New Plan is approved by a majority of voting rights of shareholders present at the Company's ordinary shareholders' meeting to be held in March 2015 (the "Ordinary Shareholders' Meeting").

The New Plan limits the period within which the Large-scale Share Purchaser (as defined in 1. below) is required by the Board of Directors to provide information to a maximum of sixty (60) business days, in principle, in order to ensure the prompt implementation of the Large-scale Share Purchase Rules (as defined in 1. below). In addition, the New Plan sets forth that, if the Board of Directors has passed a resolution to trigger the countermeasures upon the Special Committee's recommendation, the Board of Directors must promptly disclose the content of such resolution to the shareholders. Other than those, there is no substantial change from the content of the Current Plan.

Kuraray was founded in 1926 for the purpose of commercializing synthetic rayon, which was cutting-edge technology at the time. In 1950 during the post-World War II period, as Japan's first domestic producer of synthetic fiber based on original Japanese technologies, Kuraray became a world leader in the commercialization of PVA (poval) fiber under the KURALON brand, ushering in Japan's pioneering era in the chemical synthetic fiber industry. In the pharmaceutical realm, one of the products for which the company is known are the Elplasia brand products for three-dimensional culture plate needs, which have a number of micro-spaces on the surface and come in square types, such as for spheroid cultures, and slit types, such as for cell networks.

The summary of the New Plan is as follows:

1. The summary of the Company's Basic Policy and Purpose of the Introduction of the New Plan

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

3D illustration of a single cell surrounded by small molecular particles in a red biological environment.
Measuring mRNA and protein together at single cell resolution can uncover tumor-specific signaling activity and immune features.
Illustration of an antibody intertwined with a DNA double helix.
Discover how CRISPR and single-cell RNA sequencing can connect disease-associated variants to regulatory elements, genes, and pathways.
Digital illustration of the human digestive system highlighting the liver, stomach, and intestines.
Explore how human gut-liver models can improve the translation of preclinical findings into clinical pharmacokinetic predictions.